Dyadic appoints chief business officer to executive leadership team

Jupiter, fla., nov. 09, 2021 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of joe hazelton as chief business officer, effective immediately. the creation of this role supports the global commercialization of the company's new and existing business initiatives, including corporate strategy, business and corporate development and licensing. mr. hazelton will join dyadic's executive leadership team reporting directly to president and chief executive officer, mark emalfarb.
DYAI Ratings Summary
DYAI Quant Ranking